Biotech developing antibody therapies targeting Neutrophil Extracellular Traps.
| Date | Round | Amount |
|---|---|---|
| Dec 2024 | Series B Dutch biotech Citryll closed an oversubscribed EUR 85M Series B co-led by Johnson & Johnson, Forbion and Novartis Venture Fund to advance its anti-inflammatory antibody CIT-013. | $90M |